Extended blood stage sensitivity profiles of Plasmodium cynomolgi to doxycycline and tafenoquine, as a model for Plasmodium vivax - Archive ouverte HAL
Article Dans Une Revue Antimicrobial Agents and Chemotherapy Année : 2024

Extended blood stage sensitivity profiles of Plasmodium cynomolgi to doxycycline and tafenoquine, as a model for Plasmodium vivax

Résumé

ABSTRACT Testing Plasmodium vivax antimicrobial sensitivity is limited to ex vivo schizont maturation assays, which preclude determining the IC50s of delayed action antimalarials such as doxycycline. Using Plasmodium cynomolgi as a model for P. vivax , we determined the physiologically significant delayed death effect induced by doxycycline [IC 50(96 h) , 1,401 ± 607 nM]. As expected, IC 50(96 h) to chloroquine (20.4 nM), piperaquine (12.6 µM), and tafenoquine (1,424 nM) were not affected by extended exposure.
Fichier principal
Vignette du fichier
2024 AAC 68-e00280-24 Christensen.pdf (314.96 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04697336 , version 1 (24-11-2024)

Identifiants

Citer

Peter Christensen, Rosy Cinzah, Rossarin Suwanarusk, Adeline Chiew Yen Chua, Osamu Kaneko, et al.. Extended blood stage sensitivity profiles of Plasmodium cynomolgi to doxycycline and tafenoquine, as a model for Plasmodium vivax. Antimicrobial Agents and Chemotherapy, 2024, 68 (5), ⟨10.1128/aac.00280-24⟩. ⟨hal-04697336⟩
10 Consultations
0 Téléchargements

Altmetric

Partager

More